Teva Pharmaceutical Industries (NYSE:TEVA) Given Overweight Rating at Piper Sandler

Piper Sandler restated their overweight rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a $41.00 target price on the stock, up from their previous target price of $40.00.

Other analysts also recently issued research reports about the company. Scotiabank boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $32.87 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $37.35. The company has a fifty day moving average of $33.03 and a 200-day moving average of $26.07. The company has a market capitalization of $37.79 billion, a P/E ratio of 27.39, a P/E/G ratio of 10.80 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the prior year, the firm earned $0.71 earnings per share. The firm’s revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities research analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director owned 367,600 shares in the company, valued at $11,116,224. The trade was a 17.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total value of $11,633,048.40. Following the completion of the sale, the executive vice president owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. This trade represents a 85.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 767,870 shares of company stock worth $23,888,014. 0.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $1,098,060,000. Menora Mivtachim Holdings LTD. boosted its stake in shares of Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after purchasing an additional 9,303,978 shares in the last quarter. Soundwatch Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $143,533,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after buying an additional 7,255,083 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after buying an additional 6,878,304 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide $400 million to fund development of duvakitug (TL1A antibody), lowering capital risk for Teva’s late‑stage IBD program and accelerating a potential new specialty biologic growth engine. Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug
• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and nudged its price target higher to $41, signaling continued analyst confidence and providing a visible upside reference for investors. Benzinga coverage of Piper Sandler
• Neutral Sentiment: Coverage highlighting generic-drug headwinds also notes Teva’s strategic push into complex generics and biosimilars as a hedge against price pressure—this supports longer-term growth but doesn’t remove near-term margin risk. 3 Generic Drug Stocks to Watch Despite Industry Headwinds
• Neutral Sentiment: Broader industry commentary about AI adoption in pharma could benefit Teva over time through R&D efficiency and manufacturing optimization, but it’s a longer‑horizon factor rather than an immediate catalyst. Pharmaceutical Executive Daily: Pharma Industry’s AI Adoption
• Negative Sentiment: An executive (EVP Eliyahu Sharon Kalif) disclosed a large sale of 345,810 shares (~$11.6M at the trade price), which can be interpreted by some investors as insider profit‑taking and can weigh on sentiment. Teva EVP Sells 345,810 Shares
• Negative Sentiment: High‑profile investor Stanley Druckenmiller trimmed his TEVA position per 13F filings, a notable name‑level reduction that can be read as profit‑taking and may reduce momentum among discretionary institutional buyers. Billionaire Stanley Druckenmiller Dumped Teva
• Negative Sentiment: A dividend-focused piece recommends an alternative high-yield competitor over Teva, which could damp demand from income investors who are comparing yields and stability. Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.